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Abstract 
The BIRC6 gene (BRUCE/APOLLON) encodes the 
cytoplasmic protein BIRC6 in mammals, consisting 
of a single N-terminal baculoviral IAP repeat (BIR) 
domain and a C-terminal ubiquitin-conjugating 
(UBC) domain. Of the huge protein size at 528 kDa, 
BIRC6 demonstrated pleiotropic functions including 
inhibition of apoptosis, cytoprotection, regulation of 
cytokinesis, mitosis, autophagy and neutrophil 
differentiation. With the BIR domain, BIRC6 is 
defined as a member of the Inhibitor of Apoptosis 
(IAP) family. Through its BIR domain, BIRC6 binds 
to active caspases, including caspases-3, 6, 7 and 9 
and accounts for its ability to inhibit the caspase 
cascade and ultimately apoptosis. The UBC domain 
has chimeric E2/E3 ubiquitin ligase activity where it 
facilitates proteosomal degradation of various 
proteins, including pro-apoptotic proteins p53, 
caspases, Smac and mitotic regulator cyclin A. More 
importantly, the UBC domain plays an indispensable 
role in embryonic development in mammals and 
spermatogenesis in Drosophila. Increasing evidence 
supports the cancer promoting role of BIRC6. 
Elevated BIRC6 expression has been found in a 
variety of cancers and was shown to contribute to 
treatment resistance. 
Keywords 
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Identity 
Other names: APOLLON, BRUCE 
HGNC (Hugo): BIRC6 
Location: 2p22.3 
Local order 
- CARD12 (caspase recruitment domain family
member 12) (encoded on minus strand, 32303029-
32344427)
- YIPF4 (YIP1 domain family member 4)
(32356483-32385159)
- BIRC6 (32435234-32697467)
- TTC27 (tetratricopeptide repeat domain 27)
(32706633-32899620)
- LTBP1 (latent transforming growth factor beta
binding protein 1) (33025896-33478077)
DNA/RNA 
Description 
The BIRC6 gene comprises 75 exons resulting in a 
transcript of 16066 bps. The ATG is in the first exon. 
Transcription 
Only one variant of BIRC6 has been found so far 
which comprises 14490 bps. There are several 
synonymous and nonsynonymous SNPs reported for 
BIRC6 (E589K, L1742F, R2187T, T2646S, 
T3708N, E3864K, Q4323H, N4324Y, S4325C, 
N4326T, P4329R). 
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BIRC6 is a component of the apoptosis regulatory network. Multiple protein-protein interactions allow a switch from 
apoptosis inhibition to inactivation in later steps in apoptosis. BIRC6's action on activated caspases and other pro-apoptotic 
molecules might be restricted to the trans-Golgi network and the vesicular system. 
Pseudogene 
Not known. There is evidence for a processed 
pseudogene in M. musculus. 
Protein 
Description 
BIRC6 contains two functionally validated domains: 
A N-terminal BIR repeat (SMART SM00238, aa: 
256-332) and a C-terminal UBC domain (SMART
SM00212, aa: 4548 - 4712). The BIR repeat is
needed for interactions with caspases and IAP-
binding motif (IBM) containing proteins (HtrA2,
Smac). The UBC domain can form a thiolester
linkage with ubiquitin transferred by E1.
Between aa 1589-1633 a coiled-coil region can be
found.
Expression 
BIRC6 is highly expressed in brain, testis, lymphatic 
cells and secretory organs and also found in any 
other tissues (Hauser et al., 1998). It is highly 
expressed in the mouse embryos up to E11 and then 
transcript levels drop. Single-cell RNA cytometry 
analysis revealed a bi-modal distributed Birc6 
mRNA expression heterogeneity within mouse 
hematopoietic stem cell (HSC) population. Upon 
ageing, BIRC6-high expressing HSC cells were 
shown to out-compete Birc6-low cells (Dimov et al., 
2014). BIRC6 is frequently elevated in various 
cancer tissues. 
Localisation 
Localized to membranes of the trans Golgi network 
(TGN) and the endosomal system (Hauser et al., 
1998). BIRC6 relocalizes considerably during the 
cell cycle. It concentrates in a pericentriolar 
compartment in interphase, moves partially to 
spindle poles in metaphase, and finally localizes to 
the spindle midzone and the midbody in telophase 
and during cytokinesis (Pohl and Jentsch, 2008). 
Function 
Inhibitor of apoptosis. BIRC6 is a peripheral 
membrane protein of the trans-Golgi network that 
protects cells from apoptosis by functioning as an 
inhibitor of apoptosis protein (IAP). BIRC6 can bind 
and inhibit activated caspases CASP-3, CASP-6, 
CASP-7, CASP-8 and CASP-9. Furthermore it 
ubiquitylates caspase-9, HtrA2 (a pro-apoptotic 
serine protease) and DIABLO/Smac (a competitor 
for caspase-IAP interactions) thereby targeting them 
for proteasomal degradation. The ubiquityltion 
reactions do not require an ubiquitin E3 ligase 
making BIRC6 a chimeric E2/E3 ubiquitin ligase 
(Bartke et al., 2004; Hao et al., 2004). More 
importantly, distinct from other IAP members, 
BIRC6 is able to antagonize both precursor and 
mature forms of Smac and caspase-9. The ability to 
antagonize precursor apoptotic molecules represents 
an important mechanism for the prevention of 
apoptosis under normal conditions (Qiu and 
Goldberg, 2005).  
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Summary of the pleiotropic functions of BIRC6. 
On the other hand, BIRC6 also inhibits apoptosis via 
negatively regulating p53 protein levels by 
facilitating its degradation via ubiquitination (Ren et 
al., 2005; Tang et al., 2014). 
BIRC6 and treatment resistance. Silencing of 
BIRC6 has been shown to sensitize cancer cells to 
various anticancer agents, including 5-fluorouracil 
(in cervical, fibrosarcoma and breast cancer cells) 
(Chu et al., 2008), oxaliplatin and cisplatin (in 
colonospheres) (Van Houdt et al., 2011), MEK 
inhibitor, BRAFV600E-specific inhibitor and 
soluble or membrane-bound TRAIL (in melanoma 
cells) (Tassi et al., 2012), cisplatin (in non-small cell 
lung cancer and glioma) (Dong et al., 2013; Chen et 
al., 1999), camptothecin (glioma) (Chen et al., 1999) 
and sorafenib (in hepatoma) (Tang et al., 2014). 
Essential in embryonic development. Targeted 
disruption of BIRC6 in mice caused embryonic and 
neonatal lethality. BIRC6 homozygous-mutant 
embryos which did not express BIRC6 all died 
immediately after birth. At E18.5, viable mutant 
embryos had normal appearance, but were 
significantly smaller (10-20% less body weight) than 
control littermates. Macroscopic analysis of mutant 
embryos at E15.5 revealed that more than half of 
them had severely defective angiogenesis that often 
coincided with severe oedema (Hao et al., 2004). 
Consistantly, BIRC6 knock-out mice showed 
retarded growth and poor vascularization from E13.5 
and perinatal lethality (Lotz et al., 2004). BIRC6 
mutant mice were embryonic lethal (Hitz et al., 
2000; Ren et al., 2005). 
Regulator of cytokinesis. BIRC6 is a major 
regulator of abscission, the final stage of cytokinesis. 
During cytokinesis, BIRC6 moves from the 
vesicular system to the midbody ring and serves as a 
platform for the membrane delivery machinery and 
mitotic regulators. Depletion of BIRC6 in cell 
cultures causes defective abscission and cytokinesis-
associated apoptosis, accompanied by a block of 
vesicular targeting and defective formation of the 
midbody and the midbody ring. BIRC6 coordinates 
multiple steps required for abscission including the 
relocalization of ubiquitin from midbody 
microtubules to the midbody ring during cytokinesis 
(Pohl and Jentsch, 2008). 
Novel regulator of mitosis. BIRC6 interacts with 
cyclin A and promotes its degradation in early 
mitosis. BIRC6 also interacts with APC/C, and it 
facilitates cyclin A ubiquitylation. The elimination 
of cyclin A and cyclin B are essential for entry into 
mitosis. BIRC6 -deficient MEF cells exhibit earlier 
replicative senescence, large nuclei with excess 
centrosome, and mitotic delay. BIRC6 facilitates the 
ubiquitylation of CYCLIN A by recruiting it to 
APC/C without the need of a functional UBC 
domain, suggesting its role as a substrate recognition 
subunit in a complex of ubiquitin ligase (Kikuchi et 
al., 2014). 
BIRC6 and autophagy.Functional BIRC6 is 
required to inhibit autophagy under nutrient-rich 
conditions in D. melanogaster oogenesis. Lack of 
BIRC6 function in BIR-domain deleted flies resulted 
in an increase in both autophagic punctate and 
TUNEL staining in germaria and degenerating 
midstage egg chambers (Hou et al., 2008). On the 
contrary, recent evidence suggested that BIRC6 may 
promote autophagy in prostate cancer cells. 
Silencing of BIRC6 was showed to decrease Beclin-
1 protein, LC3 cleavage and reduce LC3 punctate 
formation (Low et al., 2013). 
Regulation of BIRC6 
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Despite the ability of BIRC6 to target caspases, 
Smac and HtrA2, BIRC6 is also negatively regulated 
by these pro-apoptotic molecules. Caspase-3 and 
HtrA2 are capable of cleaving BIRC6 and inhibit its 
anti-apoptotic function. Smac inhibits the IAP 
function of BIRC6 by its ability to block BIRC6-
caspase binding (Bartke et al., 2004; Sekine et al., 
2005). Nrdp1, a RING finger containing ubiquitin 
ligase, promotes proteasomal degradation of BIRC6 
(Qiu et al., 2004). 
Epstein-Barr Virus (EBV) microRNAs (miRNAs) 
processed from the BHRF1 and BamHI A rightward 
(BART) transcript, miR-BART15-3p, targets the 3' 
untranslated region (UTR) of BIRC6. miR-
BART15-3p inhibits the translation of BIRC6 
protein in EBV-infected gastric carcinoma cells and 
contributes to host cells apoptosis induction (Choi et 
al., 2013). In muscle, prostaglandin F2a upregulates 
BIRC6 which promotes muscle cell survival and 
growth (Jansen and Pavlath, 2008). 
Homology 
- ubc-17 (C. elegans)
- IAP6 (A. gambiae)
- Bruce (D. melanogaster)
- BIRC6 (X. tropicalis)
- Birc6 (M. musculus)
Mutations 
There are several synonymous and nonsynonymous 
SNPs reported for BIRC6 (E589K, L1742F, 
R2187T, T2646S, T3708N, E3864K, Q4323H, 
N4324Y, S4325C, N4326T, P4329R). 
Implicated in 
Myelodysplastic syndromes 
Bone marrow cells of myelodysplastic syndromes 
exhibit significant expression of BIRC6 (Abe et al., 
2005). 
Childhood acute myeloid leukemia 
Prognosis 
BIRC6 elevation associated with poor prognosis in 
childhood de novo Acute Myeloid Leukemia: 
BIRC6 overexpression (>median expression) was 
associated with an unfavorable day 7 response to 
induction chemotherapy and also associated with a 
poorer 3-year relapse-free survival rate (Sung et al., 
2007). 
Acute myeloid leukemia 
BIRC6 mRNA expression was associated with the 
differentiation status of AML cells. 
BIRC6 mRNA expression was induced upon 
neutrophil differentiation of AML cells, whereas 
knocking-down BIRC6 attenuates neutrophil 
differentiation of APL cells without altering cell 
survival. 
Cytogenetics 
AML patient samples with the t(8;21), the t(15;17) 
or a complex karyotype express BIRC6 significantly 
lower than normal human granulocytes (Schläfli et 
al., 2012). 
Colorectal cancer 
BIRC6 expression increased in colorectal cancer 
tissue and stem-like cells enriched colonosphere. 
BIRC6 mRNA expression was significantly up-
regulated in primary colorectal cancer tissues 
compared with normal mucosa (Bianchini et al., 
2006). Moreover, BIRC6 protein highly up-
regulated in patient derived colonosphere compared 
with differentiated counterpart. Knockdown of 
BIRC6 sensitized colonosphere against the 
chemotherapeutic drugs oxaliplatin and cisplatin in 
vitro. (Van Houdt et al, 2011). 
Brain cancers 
Elevated expression in brain cancers. 
BIRC6 knockdown induces apoptosis in 
neuroblastoma cells and associated with increased 
DIABLO protein expression in cytoplasm (Lamers 
et al., 2012). It is also overexpressed in glioma cell 
lines (SF-268, SNB-78) (Chen et al., 1999). 
Cytogenetics 
Frequent gain of the BIRC6 gene on chromosome 2 
neuroblastoma tumors, which resulted in increased 
BIRC6 mRNA expression (Lamers et al., 2012). 
Melanoma 
BIRC6 is constitutively expressed in melanoma and 
promote resistance to antitumor agents. 
BIRC6 was constitutively expressed by melanoma 
cells, in vitro and in patient samples, and at higher 
levels than in benign melanocytic lesions. Melanoma 
susceptibility to apoptosis by cytotoxic drugs 
fotemustine and target-specific inhibitors (MEK 
inhibitor and BRAFV600E-specific inhibitor) 
correlated with down-modulation of BIRC6 protein. 
The antitumor agents promoted BIRC6 
downmodulation, is caspase independent and 
proteasome dependent. Moreover, targeting of 
BIRC6, by siRNA, significantly enhanced caspase-
dependent melanoma apoptosis in response to 
cytotoxic drugs, MEK, and BRAFV600E inhibitors 
and soluble or membrane-bound TRAIL (Tassi et al., 
2012). 
Non-small cell lung cancer (NSCLC) 
Elevated expression in non-small cell lung cancer 
(NSCLC). 
BIRC6 down-regulation inhibited growth of the 
NSCLC cells and sensitized the cells to cisplatin in 
vitro. 
Prognosis 
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Elevated BIRC6 protein expression in NSCLC 
tissues was associated with poor 3-year relapse-free 
patient survival, regional lymph node metastasis, and 
advanced pathological tumor, node, metastasis stage. 
(Dong et al., 2013). 
Prostate cancer 
BIRC6 is elevated in advanced prostate cancer and 
important in promoting growth and suppressing 
apoptosis.  
Elevated BIRC6 protein expression was found in 
prostate cancer cell lines and clinical specimens 
compared to benign tissue. In particular, increased 
BIRC6 expression was associated with Gleason 6-8 
cancers, castration resistance, higher clinical T 
stages and correlates with the presence of poor 
prognostic factors including PSA recurrence, lymph 
node metastasis and prostatic capsule invasion (Low 
et al., 2013; Luk et al., 2014). 
Epithelial ovarian cancer 
Elevated expression and poor prognostic factor in 
epithelial ovarian cancer.  
BIRC6 expression was higher in the epithelial 
ovarian cancer (EOC) tissue than in normal control 
tissue at protein level. 
Prognosis 
BIRC6 was an independent significant predictor for 
overall survival and disease-free survival. 
Cytoplasmic BIRC6 expression is associated with 
EOC differentiation (Wang et al., 2014). 
Hepatocellular carcinoma (HCC) 
BIRC6 promotes hepatocellular carcinogenesis and 
associates with poor patient survival and prognosis. 
BIRC6 knockdown suppressed hepatoma cell 
proliferation, caused G1/S arrest and sensitized 
hepatoma cells to sorafenib-induced apoptosis in 
vitro and in vivo. 
Prognosis 
BIRC6 overexpression was significantly correlated 
with serum alanine aminotransferase level and HCC 
vascular invasion in patient samples. Patients with 
BIRC6 positive expression in tumor tissue had a 
poor survival and a high rate of recurrence (Tang et 
al., 2014). 
Breast cancer 
BIRC6 promotes cell growth and inhibiting 
apoptosis in breast cancer cells with wild type p53. 
BIRC6 knockdown resulted in a marked decline of 
cell growth and an increased rate of apoptosis in 
wild-type p53 ZR75.1 cells, which was associated 
with p53 stabilisation and activation of the 
mitochondrial-dependent apoptotic pathway. A less 
pronounced anti-proliferative and pro-apoptotic 
effects were observed in mutant p53 breast cancer 
cells (Lopergolo et al., 2009). 
Pseudoexfoliative glaucoma (PEXG) 
Polymorphism in the BIRC6 Gene plays a protective 
role in Pseudoexfoliative Glaucoma. 
Prognosis 
TT allele of the rs2754511 in the BIRC6 gene plays 
a protective role in PEXG patients of the Pakistani 
population (Ayub et al., 2014). 
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